Icecure Medical Ltd Ord (ICCM) Stock Price, Quote & News

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Fax: 972 4 623 0222

Website: www.icecure-medical.com

Address:

7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel

SmartMoneyPicks Sep. 13 at 6:01 AM

MITQ has all the ingredients needed for a parabolic move. What a bullish close Friday, on our way to 52 weeks high and then it's going to squeeze up fast. MITQ 💥 Small float 💥 NO Dilution 💥 Cash-Flow Positive 💥 High Insider Ownership 💥 golden cross forming on the daily-Bullish. The chart is looking explosive, you don't want to miss out on this one! Lets go bulls be early next week. Also watching $SPRC $WHLR $ICCM $YHC

1 · Reply

Aimoney Sep. 12 at 9:21 PM

$ICCM Buying more next week on open. Have a great weekend, oh it went up? Should l take profits...hell nah😅

0 · Reply

Leemarvin70 Sep. 12 at 8:35 PM

$ICCM 🤣🤣 compralas todas

0 · Reply

Aimoney Sep. 12 at 6:40 PM

$ICCM bought more here

0 · Reply

Bbking241 Sep. 11 at 5:42 PM

$ICCM This is losing momentum baby.

1 · Reply

Bbking241 Sep. 11 at 1:12 PM

$ICCM Weekly candle is red, so this just tells you what type of week this will be. A weak week.

0 · Reply

Scuba_St3v3 Sep. 10 at 8:55 PM

$ICCM is going to 1.20-1.25 in the next 2-4 weeks without news of fda approval. …that’s 20-25%. You’re welcome $WULF $AREC

0 · Reply

Aimoney Sep. 10 at 7:31 PM

$ICCM 😅

0 · Reply

Wut_About_Bob Sep. 10 at 4:18 PM

$ICCM Why would a stop loss be needed for a stock where FDA approval for market authorization is a lock?

1 · Reply

Bbking241 Sep. 10 at 3:11 PM

$ICCM The boat's sinking slowly fellas. Make sure you have your stop loss.

0 · Reply

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 4, 2025, 8:30 AM EDT - 10 days ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Aug 13, 2025, 1:08 PM EDT - 4 weeks ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 8:30 AM EDT - 4 weeks ago

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 6, 2025, 8:30 AM EDT - 5 weeks ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Jul 29, 2025, 9:00 AM EDT - 6 weeks ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 25, 2025, 9:00 AM EDT - 7 weeks ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 24, 2025, 9:00 AM EDT - 7 weeks ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 10, 2025, 8:00 AM EDT - 2 months ago

IceCure Announces Commencement of Rights Offering

Jul 3, 2025, 8:30 AM EDT - 2 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jun 25, 2025, 9:23 AM EDT - 2 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 9, 2025, 8:30 AM EDT - 3 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

May 28, 2025, 4:26 PM EDT - 3 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 8:30 AM EDT - 3 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

May 21, 2025, 8:30 AM EDT - 4 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 6, 2025, 8:30 AM EDT - 4 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Apr 30, 2025, 8:30 AM EDT - 4 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 4 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 22, 2025, 8:30 AM EDT - 5 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Mar 27, 2025, 1:45 PM EDT - 6 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 24, 2025, 8:30 AM EDT - 6 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 21, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 20, 2025, 8:30 AM EDT - 6 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 18, 2025, 8:30 AM EDT - 6 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 17, 2025, 8:30 AM EDT - 6 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Mar 10, 2025, 8:30 AM EDT - 6 months ago

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

Feb 24, 2025, 8:30 AM EST - 7 months ago

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

Feb 4, 2025, 8:30 AM EST - 7 months ago

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

Jan 27, 2025, 8:30 AM EST - 8 months ago

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

Jan 13, 2025, 7:00 AM EST - 8 months ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

Jan 6, 2025, 8:30 AM EST - 8 months ago

IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule

Jan 3, 2025, 8:30 AM EST - 9 months ago

European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology

Dec 16, 2024, 8:30 AM EST - 9 months ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

Nov 26, 2024, 1:46 PM EST - 10 months ago

IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript

Nov 26, 2024, 8:30 AM EST - 10 months ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

Nov 25, 2024, 8:30 AM EST - 10 months ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

Nov 20, 2024, 8:30 AM EST - 10 months ago

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

Nov 19, 2024, 8:30 AM EST - 10 months ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

Nov 8, 2024, 7:00 AM EST - 11 months ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Oct 29, 2024, 8:30 AM EDT - 11 months ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

Oct 21, 2024, 8:30 AM EDT - 11 months ago

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

Oct 7, 2024, 8:15 AM EDT - 1 year ago

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

Sep 24, 2024, 8:15 AM EDT - 1 year ago

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

Sep 12, 2024, 8:00 AM EDT - 1 year ago

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

Sep 4, 2024, 8:30 AM EDT - 1 year ago

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

Aug 28, 2024, 8:30 AM EDT - 1 year ago

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

Aug 20, 2024, 3:29 PM EDT - 1 year ago

IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 8:30 AM EDT - 1 year ago

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

SmartMoneyPicks Sep. 13 at 6:01 AM

1 · Reply

Aimoney Sep. 12 at 9:21 PM

$ICCM Buying more next week on open. Have a great weekend, oh it went up? Should l take profits...hell nah😅

0 · Reply

Leemarvin70 Sep. 12 at 8:35 PM

$ICCM 🤣🤣 compralas todas

0 · Reply

Aimoney Sep. 12 at 6:40 PM

$ICCM bought more here

0 · Reply

Bbking241 Sep. 11 at 5:42 PM

$ICCM This is losing momentum baby.

1 · Reply

Bbking241 Sep. 11 at 1:12 PM

$ICCM Weekly candle is red, so this just tells you what type of week this will be. A weak week.

0 · Reply

Scuba_St3v3 Sep. 10 at 8:55 PM

$ICCM is going to 1.20-1.25 in the next 2-4 weeks without news of fda approval. …that’s 20-25%. You’re welcome $WULF $AREC

0 · Reply

Aimoney Sep. 10 at 7:31 PM

$ICCM 😅

0 · Reply

Wut_About_Bob Sep. 10 at 4:18 PM

$ICCM Why would a stop loss be needed for a stock where FDA approval for market authorization is a lock?

1 · Reply

Bbking241 Sep. 10 at 3:11 PM

$ICCM The boat's sinking slowly fellas. Make sure you have your stop loss.

0 · Reply

francisplastering Sep. 10 at 2:18 PM

$ICCM I was going to invest in this stock when it goes back under 1. Can anyone tell me why this is a good stock to hold? Or should I put my money somewhere else

1 · Reply

Aimoney Sep. 10 at 9:22 AM

$ICCM Buying and Holding.

0 · Reply

jimmy129 Sep. 9 at 11:50 PM

$ICCM Be patient this will be $60 next year

0 · Reply

Non_Sequitur8 Sep. 9 at 8:06 PM

$ICCM Is there any word on whether or not these guys have submitted the additional information the FDA is requesting? Also, is it possible that the FDA decides to approve it for a larger age group? Or is if/when approval comes, it's only going to be for 70+?

2 · Reply

justme_DC Sep. 9 at 7:35 PM

$ICCM Just for dialogue. It will be interesting to see how much of an FDA approval is already baked in. Considering a very large majority on this forum (and others) already believe it is a foregone concluion. And true MM's are way smarter than us lol. That and amount of intraday spike there is after (if) announcing versus a full day or two of settling in and averaging out. Not meaning it bearish of course....will be interesting.

2 · Reply